Eduardo Lobo

Jesús Frutos Díaz-Alejo^*,1,2,3,4, 

Simon April-Monn^*,5, 

Marina Cihova⁶, 

Verona Buocikova⁶, 

Jorge Villalón López^1,3, 

Maria Urbanova⁶, 

Carmen G. Lechuga⁷, 

Miroslav Tomas^6,8, 

Peter Dubovan^6,8, 

Bárbara Luna Sánchez³, 

Sonia Camaño Páez³, 

Alfonso Sanjuanbenito^2,9, 

Eduardo Lobo⁹, 

Estefanía Romio de la Heras¹⁰, 

Carmen Guerra^2,7, 

Carolina de la Pinta¹¹, 

Emma Barreto Melian^1,2, 

Mercedes Rodríguez Garrote^1,2, 

Alfredo Carrato^1,2,4, 

Laura Ruiz-Cañas^3,12,13, 

Bruno Sainz, Jr.^2,3,12,13, 

Ana Torres³, 

Bozena Smolkova⁶, 

Julie Earl^1,2,3 

¹Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS), 

², The Biomedical Research Network in Cancer (CIBERONC), 

³Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS), 

⁴Faculty of Medicine, University of Alcalá de Henares, 

⁵Institute of Tissue Medicine and Pathology, University of Bern, 

⁶Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 

⁷Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 

⁸Department of Surgical Oncology, National Cancer Institute, Slovak Medical University, 

⁹Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal, 

¹⁰Department of Pathology, Hospital Universitario Ramón y Cajal, 

¹¹Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, 

¹²Department of Cancer, Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), 

¹³Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS